HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence
This study will evaluate the efficacy and safety of therapy perioperative treatment with HAIC combined with donafenib and sintilimab (group A)/ donafenib combined with sintilimab (group B) compared with direct surgery (group C) in resectable HCC patients who are at high risk for disease recurrence.
Hepato Cellular Carcinoma (HCC)
DRUG: HAIC combined with sintilimab and donafenib|DRUG: Sintilimab and Donafenib|PROCEDURE: Surgery
1-yr RFS rate, the proportion of patients who have not experienced recurrence or death from any cause at 12 months after hepatectomy., 24 months
MPR rate, The percentage of patients with 70%-99% tumor necrosis found during surgery after neoadjuvant therapy, Up to approximately 12 weeks|pCR rate, the percentage of participants having a pathCR, Up to approximately 12 weeks|ORR, The percentage of subjects in the overall population who achieved CR or PR according to the mRECIST criteria, Up to approximately 12 weeks|RFS, RFS is defined as the time from liver resection to the first documented occurrence of intrahepatic or extrahepatic HCC, or death from any cause (whichever occurs first)., Up to approximately 2 years|PFS, PFS is defined as the time from randomization to the first documented occurrence of intrahepatic or extrahepatic HCC, or death from any cause (whichever occurs first)., Up to approximately 2 years|OS, OS is defined as the time from randomization to death from any cause., Up to approximately 3 years|TTR, TTR is defined as the time from liver resection to the first documented occurrence of intrahepatic or extrahepatic HCC., Up to approximately 2 years
This study will evaluate the efficacy and safety of therapy perioperative treatment with HAIC combined with donafenib and sintilimab (group A)/ donafenib combined with sintilimab (group B) compared with direct surgery (group C) in resectable HCC patients who are at high risk for disease recurrence.